Formulation and evaluation of opthalmic insert drug delivery system of forskolin

Article Sidebar

PDF
Published: Aug 25, 2014
DOI: https://doi.org/10.22377/ajp.v2i4.201

Main Article Content

Vijay D Wagh
Kalpana V Wagh
Prangya P Patil
Malay K Samanta

Abstract

Forskolin, a diterpene obtained from natural roots of Coleus forskohlii (wild) Briq. (family: Lamiaceae), reduces intraocular pressure (IOP) by 23-28%, which is a desirable feature for an antiglaucoma therapy. Polyvinyl alcohol-14000 based
ophthalmic inserts of pure forskolin (PVA-OIF) were prepared as matrix drug delivery with the aim of achieving once a day administration. Ophthalmic inserts were prepared using polymer PVA in various concentrations. The ophthalmic inserts were evaluated for evaluation parameters and in vitro drug release. One-way ANOVA tested in vitro release characteristics statistically. The in vitro release data was treated according to diffusion model proposed by Higuchi and Peppas in order
to access the mechanism of drug release. The batch formulated with PVA-14000 (1.5%), showed sustained drug release behavior over a period of 6 hrs.

Downloads

Download data is not yet available.

Article Details

How to Cite
Wagh, V. D., Wagh, K. V., Patil, P. P., & Samanta, M. K. (2014). Formulation and evaluation of opthalmic insert drug delivery system of forskolin. Asian Journal of Pharmaceutics (AJP), 2(4). https://doi.org/10.22377/ajp.v2i4.201
Issue
Vol. 2 No. 4 (2008): Oct-Dec
Section
Articles

This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.

References

Loss of vision, Current R and D Highlights: Ophthalmic Disorders, 2003

July –Sept., 26.

Rubin I. Wellcome trends in pharmacy. 1989 June, 2-6.

Shield SB. Textbook of Glaucoma, 3ed ed. Philadelphia: Williams and

Wilkins; 1992. p. 1-9.

Saettone MF, Burgalassi S, Giannaecinni B. Preparation and evaluation

in rabbits of topical solutions containing forskolin. J Ocul Pharmacol

;5:111-8.

Shun Matasumoto, Tora Yamashita, Makoto Araie, Shunichi Kametuni,

Tomokazu Hosokawa, Masahiro Takase. The ocular penetration of topical

forskolin and its effects on intra ocular pressure, aqueous rate and cyclic

AMP level in the rabbit eye. Jpn J Opthalmol 1990;34:428-35.

Zeng S. Experimental studies of the effect of forskolin on the lowering

of intra ocular pressure. Yen-Ko-Husuch-Pao 1995;11:173-6.

Meyer BH, Stulting AA, Muller FO, Luss HG, Badian M, The effects

of forskolin eye drops on intra ocular pressure. South Afr Med J

;71:570-1.

Shibata T, Mishima H, Kurokawa T. Ocular pigmentation and intra ocular

pressure response to forskolin. Curr Eye Res 1988;7:667-4.

Potter DE, Burke JA, Temple JR. Forskolin suppresses sympathetic neuron function and causes ocular hypotension. Curr Eye Res 1985;4:87-96.

Caprioli J, Sears M, Bausher L, Gregory D, Mead A. Forskolin lowers

intra ocular pressure by reducing aqueous inflow. Invest Opthalmol Vis

Sci 1984;25:268-76.

Dubey MP, Srimal RC, Nityanand S, Dhawan BN. Pharmacological

studies on colenol a hypotensive diterpene from Coleus forskohliI. J

Ethanopharmacol 1981;3:1-13.

Seamon KB, Daly JW. Forskolin: A unique diterpene activator of cyclic

AMP generating systems. J Cyclic Nucl Res 1981;7:220-1.

Caprioli J, Sears M. Forskolin lowers intra ocular pressure in rabbits,

monkeys and man. Lancet 1983;30:958-60.

Bartel SP, Lee SR, Neufeld AH. Forskolin stimulate cyclic AMP synthesis

lowers intra ocular pressure and increases outflow facility in rabbits.

Curr Eye Res 1982;2:673-81.

Burstein NL, Sears ML, Mead A. Aqueous flow in human eyes is

reduced by forskolin a potent adenylate cyclase activator. Exp Eye Res,

;39:745-9.

Caprioli J, Sears M. Combined effect of forskolin and acetazolamide

on intra ocular pressure and aqueous flow in rabbit eyes. Exp Eye Res

;39:47-50.

Caprioli J, Sears M, Bausher L, Gregory D, Mead A. Forskolin lowers

intra ocular pressure by reducing aqueous inflow. Invest Opthalmol Vis

Sci 1984;25:268-77.

Lee PY, Podos SM, Mittag T, Severin C. Effect of topical applied forskolin

on aqueous humor dynamics in cynomolgus monkey. Invest Opthalmol

Vis Sci 1984;25:1206-9.

Smith BR, Gaster RN, Leopold IH, Zeleznick LD. Forskolin a potent

adenylate cyclase activator lowers rabbit intra ocular pressure. Arch

Opthalmol 1984;102:116-8.

Brubaker RF, Carlson KH, Kullerstrand LJ, McLaren JW. Topical

forskolin (corforsin) and aqueous flow in humans. Arch Opthalmol

;105:637-41.

Samanta MK, Wagh VD, Pruthviraju D, Suresh B. Pharmacokinetics of

herbal drugs: An Introduction. Indian J Pharm Educ 2004;38:16-8.

Sultana Y, Zafar S, Ali A. Enhanced ocular bioavailability with sol to gel

system of Pefloxacin mesylate: In-vitro and in-vivo studies. J Sci Pharm

;4:5-10.

Lee YC, Millard JW, Negvesky GJ, Butrus SI, Yalkowsky SH. Formulation

and in vivo evaluation of ocular insert containing phenylephrine and

tropicamide. Int J Pharm 1999;182:121-6.

Gurny R, Baeyens V, Kaltsatos V, Boisrame B, Fathi M. Evaluation of

soluble bioadhesive ophthalmic drug inserts (BODIR) for prolonged

release of gentamicin: Lachrymal pharmacokinetics and ocular

tolerance. J Ocul Pharmacol Ther 1998;14:263-72.

Hiratani H, Fujiwara A, Tamiya Y, Mizutaniand Y, Alvarez C. Ocular release

of timolol from molecularly imprinted soft contact lenses. Biomaterials

;26:1293-8.

Grzeskowiak E. Technology and biopharmaceutical availability of solid

ocular inserts containing sulfadicramide and some promoters. Acta Pol

Pharm 1998;55:205-10.

Wang G, Tucker IG, Roberts MS, Hirst LW. In vitro and in vivo evaluation

in rabbits of a controlled release 5-flurouracil subconjunctival implant

based on poly (D, L-lactide-co-glycolide). Pharm Res 1996;13:1059-64.

Hornhof M, Weyenberg W, Ludwig A, Schnuerch BA. Mucoadhesive

ocular insert based on thiolated poly (acrylic acid): development and

in vivo evaluation humans. J Control Release 2003;89:419-28.

Haesslein A, Ueda H, Hacker MC, Jo S, Ammon DM, Borazjani RN, et

al. Long-term release of fluocinolone acetonide using biodegradable

fumarate-based polymers release. J Control Release 2006;114:251-60.

Manavi FV, Soppimath KS, Gadad AP. Development and evaluation of

timolol maleate ocular inserts. Indian Drugs 1997;34:264-8.

Lalla JK, Seethalakshmi. Nitroglycerine controlled release of transdermal

patches. Indian Drugs 1989;26:284-95.

Khanna R, Agarwal, SP, Ahuja A. Preparation and evaluation of

mucoadhesive buccal films of clotrimazole for oral Candida infections.

Indian J Pharm Sci 1997;59:299-305.

Ahuja A, Dogra M, Agarwal SP. Development of buccal tablets of diltizem

hydrochloride. Indian J Pharm Sci 1995;57:26-30.

Higuchi T. Mechanism of sustained-action medication theoretical

analysis of rate of release of solid drugs dispersed in solid matrices. J

Pharm Sci 1963;52:1145-9.

Peppas NA. Analysis of Fickian and non-Fickian drug release from

polymers. Pharm Acta Helv 1985;60:110-1.